Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. - Wikidata - wikimedia - TriplyDB

Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma.

Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma.

http://www.wikidata.org/entity/Q35760631

about

Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients A review of responsive MRI contrast agents: 2005-2014 Detecting enzyme activities with exogenous MRI contrast agents Recapitulation of tumor heterogeneity and molecular signatures in a 3D brain cancer model with decreased sensitivity to histone deacetylase inhibition NETRIN-4 protects glioblastoma cells FROM temozolomide induced senescence Advances in Magnetic Resonance Imaging Contrast Agents for Biomarker Detection Magnetic Resonance (MR) Metabolic Imaging in Glioma.Interrogating Metabolism in Brain Cancer.MR Molecular Imaging of Brain Cancer Metabolism Using Hyperpolarized 13C Magnetic Resonance Spectroscopy.Interrogating IDH Mutation in Brain Tumor: Magnetic Resonance and Hyperpolarization.Phospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy Chemical mapping of the colorectal cancer microenvironment via MALDI imaging mass spectrometry (MALDI-MSI) reveals novel cancer-associated field effects Cellular protection using Flt3 and PI3Kα inhibitors demonstrates multiple mechanisms of oxidative glutamate toxicity.Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.Alterations in cellular metabolome after pharmacological inhibition of Notch in glioblastoma cells.Recent Advances in Targeting Tumor Energy Metabolism with Tumor Acidosis as a Biomarker of Drug Efficacy.Metabolic response of glioma to dichloroacetate measured in vivo by hyperpolarized (13)C magnetic resonance spectroscopic imaging MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival.Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.Hyperpolarized NMR probes for biological assays.Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation.Characterization of metabolites in infiltrating gliomas using ex vivo ¹H high-resolution magic angle spinning spectroscopy.Effects of deranged metabolism on epigenetic changes in cancer.In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic resonance spectroscopy.Differentiating inflamed and normal lungs by the apparent reaction rate constants of lactate dehydrogenase probed by hyperpolarized (13)C labeled pyruvate.Assessing Metabolic Changes in Response to mTOR Inhibition in a Mantle Cell Lymphoma Xenograft Model Using AcidoCEST MRI.Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics.Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells.Lactate and choline metabolites detected in vitro by nuclear magnetic resonance spectroscopy are potential metabolic biomarkers for PI3K inhibition in pediatric glioblastoma.Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma MR-detectable metabolic consequences of mitogen-activated protein kinase kinase (MEK) inhibition.Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters.Characterization of the serum metabolome following radiation treatment in patients with high-grade gliomas.Commentary: Targeting LDH enzymes with a stiripentol analog to treat epilepsy.Probing the PI3K/Akt/mTor pathway using (31)P-NMR spectroscopy: routes to glycogen synthase kinase 3.MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy.Differentiating diffuse World Health Organization grade II and IV astrocytomas with ex vivo magnetic resonance spectroscopy.In vivo Metabolic Profiles as Determined by (31)P and short TE (1)H MR-Spectroscopy : No Difference Between Patients with IDH Wildtype and IDH Mutant Gliomas.Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models.

P2860

Q26853308-03986664-99F7-439E-A29D-7992B8CBC560 Q27009286-F7401AF6-12A8-4674-B999-43D5E44FF341 Q27021691-3768CD86-9716-40B9-803A-2BD1307C4FDB Q28484418-22213796-1FB1-451D-A520-83863B2E1429 Q28535039-F9B5DD30-723D-48D8-B296-ADDA9DEBDB6A Q28830010-3167697A-6E7F-4905-A25A-274A4EC71490 Q31015256-D999732F-739F-4132-A929-C12D248C58D3 Q31136705-6B8D53E7-AE40-4313-A261-982B00D4ECF6 Q31137181-36BDD226-3F97-4355-ABC2-EACF54DF32BD Q31154376-12074315-37AD-4E52-B0BF-F98151ED2260 Q34631627-E0D20EA1-F81F-447F-AE28-A8479AF6B3D7 Q35013696-53FDC734-4359-4DD2-87AE-5BEA95427333 Q35150284-0979DED5-B2FC-40B4-90DB-44919BF5904F Q35587235-7D8AC3BD-4F23-42A2-85A9-67A9C1E92203 Q36633528-5E85154F-8829-492F-B61F-C6EC1D7D4648 Q36658324-AF7ADFCC-C323-427B-9DDA-68621AC832B7 Q36713482-2F94E2AF-E1B8-4E2A-A128-DDD8EDF3EB9F Q36918102-CE7D7487-922B-42BE-88BD-8FA66D7FDA5E Q37081252-0226091F-8429-4744-8D03-C0A8ABE26F8A Q37588737-51A3DB0F-0047-4E46-A69D-7D3ACC48B09E Q37660266-E899B229-85D5-4900-9E62-61CA583F1D24 Q37697784-2883E119-21BF-443C-9E12-D338FC8D0E86 Q38335029-C093444A-79BD-4170-A923-0AFBCEB6451B Q38680891-24E4F1EC-5B6C-437B-9E73-A48B512A9E95 Q38720885-874B1CFA-C626-49D4-8209-618716DA1A9C Q38729363-45F50B52-603C-43E7-843E-CF17851AF4BA Q38773520-3543CB37-44BB-43A3-B4DA-057716F1F0DB Q38840489-A00BFEC9-8FFA-4494-812C-0E21D3FF226F Q38947387-FF742C6F-AB94-4D26-95B0-F6D25B3183F7 Q38969526-CA526CBC-5268-4C13-B679-4AC5E37D5F5D Q38990221-C31C5DA5-10D1-4038-8637-8949D9A4089E Q39007170-AD8933EB-616B-4762-8514-0D9ADD569CC5 Q39796059-094693F8-15D5-449C-894B-F28CC13884FF Q39817583-EC8CD5F5-BEA5-4243-9D8B-89941737AF54 Q41336182-60DBC941-5F0A-4B73-B918-33F062715364 Q42120404-D16FE7C4-68BB-46AB-8046-CA552844C45B Q43296499-9B5DE964-703A-48B5-9B69-F8E862C4F86F Q44844537-173F6CEF-D7D6-490A-9213-6C97A4E0778D Q47853442-C83199B7-F113-4F98-A0FB-8FB7FAB62027 Q49393542-12B8E668-2089-4BBC-8C56-3474DDB4F98A

P2860

Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma.

http://www.wikidata.org/entity/Q35760631

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Reduced phosphocholine and hyp ...... OR inhibition in glioblastoma.

@ast

Reduced phosphocholine and hyp ...... OR inhibition in glioblastoma.

@en

type

label

Reduced phosphocholine and hyp ...... OR inhibition in glioblastoma.

@ast

Reduced phosphocholine and hyp ...... OR inhibition in glioblastoma.

@en

prefLabel

Reduced phosphocholine and hyp ...... OR inhibition in glioblastoma.

@ast

Reduced phosphocholine and hyp ...... OR inhibition in glioblastoma.

@en

P1433

Q35760631-1BF04060-087D-4707-8F19-2B46D3296555

P1476

Q35760631-8710E55A-F30D-47EE-807C-6336CAC40EF2

P2093

Q35760631-00DE69ED-2AC4-4F8B-896E-8FA7D45457C8

Q35760631-0658D7BB-C75D-466D-BEE8-EAA7C6D61478

Q35760631-1E075C66-442A-4646-991F-9B99F2FAC557

Q35760631-96745622-AA4B-4572-8412-BF6AE6A19224

Q35760631-AA876C66-58A1-4F1B-9ADC-3A9F7DF457A7

Q35760631-B4CD2FF6-3B02-49AC-9BE7-BCEDCC59E84E

P2860

Q35760631-046F50AA-3C2B-40B2-8629-ABD37A4832E8

Q35760631-0DFFD61B-17B3-4B60-9E7B-5DA3B343A634

Q35760631-16540BCF-B96D-4040-AA07-EED39A6D69AC

Q35760631-16A247D6-969B-49FE-B155-650230FD7174

Q35760631-1FD9AC51-BF70-476A-B8E8-2E5A032313A6

Q35760631-2339F09C-3D77-40B3-8069-BAF70CBAA526

Q35760631-23AED65F-DBC5-40D1-A329-61B3909F304A

Q35760631-29AF19CA-209E-4A21-A940-242A9F1E178E

Q35760631-2D84C354-4C4F-46F6-8CCC-C65EA4AF3D4A

Q35760631-377F9B4E-7DF0-464E-9BC0-8D310ED59F08

P304

Q35760631-C420108C-E6AC-40C2-9185-8C59B5C7BC9A

P31

Q35760631-C1DD8CF7-DCC4-4988-BA0C-C8EE84CCDD17

P356

Q35760631-4A5F2A23-FBB6-4B32-A2C3-5612EEC111BB

P433

Q35760631-E4FAE53D-8A74-43AA-9373-C0E2B14DF945

P478

Q35760631-1A687CB5-9C41-4B45-BDAA-58AE0ADBDC27

P577

Q35760631-DCD982BA-10C0-4598-AE6E-84874AFEC2A4

P5875

Q35760631-E0FD16F9-1B53-4DFD-99E2-3EC41E130EE9

P698

Q35760631-DA0BB63A-487B-4187-90C7-770212319668

P921

Q35760631-184EE8E0-1D3C-4B93-979E-2A1609F026E1

P932

Q35760631-1C800E9B-D496-4DF9-8C5C-157E8DADDEC4

P356

P1433

P1476

Reduced phosphocholine and hyp ...... OR inhibition in glioblastoma.

@en

P2093

C David James

http://www.w3.org/2001/XMLSchema#string

Christopher S Ward

http://www.w3.org/2001/XMLSchema#string

Daphne A Haas-Kogan

http://www.w3.org/2001/XMLSchema#string

Humsa S Venkatesh

http://www.w3.org/2001/XMLSchema#string

Myriam M Chaumeil

http://www.w3.org/2001/XMLSchema#string

Sabrina M Ronen

http://www.w3.org/2001/XMLSchema#string

P2860

Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR

Malignant astrocytic glioma: genetics, biology, and paths to treatment

Tumor cell metabolism: cancer's Achilles' heel

Regulation of translation initiation by FRAP/mTOR

CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

Multivoxel magnetic resonance spectroscopy of brain tumors.

Studies of human tumors by MRS: a review.

Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo.

P304

315-325

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOR209

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51866698

http://www.w3.org/2001/XMLSchema#string

P698

22156546

http://www.w3.org/2001/XMLSchema#string

P921

P932

3280799

http://www.w3.org/2001/XMLSchema#string